Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases<sup>§</sup>
Michael Hertl(Philipps University of Marburg), Sonja Wolff‐Franke(Philipps University of Marburg), Rüdiger Eming(Philipps University of Marburg), Marcel Reiser(University Hospital Cologne), Iakov Shimanovich(University of Lübeck), Michael Sticherling(Hochschule für Angewandte Wissenschaften Kiel), Leena Bruckner‐Tuderman(University Medical Center Freiburg), Martin Pfütze(Universitätsklinikum Gießen und Marburg), Undine Lippert(Städtisches Klinikum Dessau), Nicolas Hunzelmann(University Hospital Cologne), Andreas Engert(University Hospital Cologne), Ocko Kautz, Franz Karlhofer(Medical University of Vienna), Enno Schmidt(University Hospital Schleswig-Holstein), Silke Hofmann(Helios Universitätsklinikum Wuppertal), Matthias Goebeler(Universitätsklinikum Würzburg), Luca Borradori(University Dermatology), Detlef Zillikens(University of Lübeck), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Martin Nitschke(University Hospital Schleswig-Holstein), A. Niedermeier(Philipps University of Marburg), Harald Burckhard(Goethe University Frankfurt)
JDDG Journal der Deutschen Dermatologischen Gesellschaft
January 16, 2008
Cited by 137
Related Papers
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification
|Journal of the American Academy of Dermatology|2014|933
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB
|Journal of the American Academy of Dermatology|2008|933
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
|British Journal of Dermatology|2020|778